Kristin Emiko Hirabayashi, MD
Ophthalmology · Honolulu
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Cornea and Refractive Surgery Consultants of the Pacific, Inc. · 3 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hirabayashi’s office at (808) 735-1935 to ask if they take your plan before you enroll.
California Medical Board record
Licence A139451 · Cancelled
Licence status: Cancelled · since 2015 · University of California, Irvine College of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$120,484
Medicare paid this office $120,484 for 304 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient problem focused exam of visual system | 143 | $15,726 | $65 |
| Complex removal of cataract with insertion of prosthetic lens | 15 | $13,264 | $577 |
| Removal of cataract with insertion of prosthetic lens | 19 | $11,440 | $440 |
| Established patient complete exam of visual system | 117 | $10,791 | $91 |
| Return visit (30+ min) | 89 | $9,849 | $103 |
See all 20 services
| Established patient problem focused exam of visual system | 143 | $15,726 | $65 |
| Complex removal of cataract with insertion of prosthetic lens | 15 | $13,264 | $577 |
| Removal of cataract with insertion of prosthetic lens | 19 | $11,440 | $440 |
| Established patient complete exam of visual system | 117 | $10,791 | $91 |
| Return visit (30+ min) | 89 | $9,849 | $103 |
| Imaging of optic nerve | 134 | $5,925 | $28 |
| Short return visit (20+ min) | 54 | $4,888 | $72 |
| Exam of visual field with extended testing | 94 | $4,665 | $47 |
| Photography of the retina | 123 | $3,985 | $29 |
| New patient complete exam of visual system | 39 | $3,652 | $94 |
| New patient visit (45+ min) | 28 | $3,202 | $114 |
| Imaging of retina | 85 | $2,961 | $31 |
| Short return visit | 37 | $2,162 | $46 |
| Measurement of corneal curvature and depth of eye | 33 | $1,750 | $20 |
| Ct scan of cornea | 55 | $1,710 | $27 |
| Ultrasound scan of cornea to determine thickness | 70 | $632 | $8 |
| Exam of the internal drainage system of eye | 28 | $601 | $21 |
| Imaging of front third of eye using a special microscope | 17 | $558 | $33 |
| Photography of content of eyes | 13 | $350 | $21 |
| Imaging of front third of eye | 12 | $268 | $22 |
Procedures Medicare counted
| Cataract surgery | 81 | More than 71% of doctors who do this |
Who their Medicare patients are
304 Original Medicare patients in 2024. Average age 77 · Women 56% · Health risk score 0.95. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 72% · Diabetes 36% · Chronic kidney disease 33% · Coronary heart disease 19% · Atrial fibrillation 15% · Cancer 14% · COPD 8% · Heart failure 7% · Depression 6% · Stroke 6% · Dementia 5%.
The office billed $407,452, Medicare allowed $161,975 and paid $120,484; for 1,650 services of 45 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 304 | 1,650 | 77 | 0.95 | $407,452 | $120,484 |
| 2023 | 262 | 1,285 | 76 | 0.98 | $285,336 | $95,609 |
| 2022 | 95 | 325 | 74 | 1.16 | $85,258 | $28,851 |
| 2021 | 195 | 636 | 74 | 0.93 | $127,623 | $48,350 |
| 2020 | 69 | 224 | 75 | 1.33 | $55,539 | $19,468 |
| 2019 | 102 | 167 | 73 | 1.50 | $143,331 | $13,578 |
| 2018 | 53 | 64 | 76 | 1.17 | $73,595 | $5,327 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Established patient problem focused exam of visual system | 155 | $19,550 | $68 |
| New patient complete exam of visual system | 136 | $14,537 | $107 |
| Removal of cataract with insertion of prosthetic lens | 17 | $11,775 | $453 |
| Established patient complete exam of visual system | 70 | $7,124 | $94 |
| Exam of visual field with extended testing | 85 | $4,747 | $53 |
| Closure of tear duct opening using plug | 15 | $4,010 | $98 |
| Imaging of retina | 94 | $3,361 | $32 |
| New patient visit (45+ min) | 25 | $3,212 | $128 |
| Imaging of optic nerve | 73 | $2,569 | $28 |
| Measurement of corneal curvature and depth of eye | 29 | $1,677 | $20 |
| Photography of the retina | 45 | $1,357 | $30 |
| Ultrasound scan of cornea to determine thickness | 104 | $977 | $9 |
| Exam of the internal drainage system of eye | 37 | $868 | $23 |
| Ct scan of cornea | 14 | $425 | $27 |
2022: 7 services
| Established patient complete exam of visual system | 43 | $4,669 | $101 |
| Established patient problem focused exam of visual system | 46 | $4,537 | $61 |
| New patient complete exam of visual system | 11 | $1,344 | $122 |
| Imaging of retina | 23 | $774 | $32 |
| Measurement of corneal curvature and depth of eye | 11 | $541 | $18 |
| Imaging of optic nerve | 14 | $441 | $26 |
| Ultrasound scan of cornea to determine thickness | 11 | $135 | $8 |
2021: 11 services
| Established patient problem focused exam of visual system | 89 | $11,873 | $74 |
| Established patient complete exam of visual system | 76 | $7,594 | $96 |
| Return visit (30+ min) | 24 | $3,927 | $112 |
| New patient visit (45+ min) | 27 | $3,759 | $139 |
| New patient complete exam of visual system | 18 | $1,939 | $108 |
| Measurement of corneal curvature and depth of eye | 24 | $1,681 | $32 |
| Imaging of optic nerve | 39 | $1,639 | $32 |
| Imaging of retina | 40 | $1,330 | $32 |
| Exam of visual field with extended testing | 17 | $1,087 | $57 |
| Ct scan of cornea | 19 | $609 | $28 |
| Ultrasound scan of cornea to determine thickness | 27 | $374 | $9 |
2020: 4 services
| Established patient problem focused exam of visual system | 34 | $4,901 | $73 |
| Established patient complete exam of visual system | 27 | $2,768 | $95 |
| Imaging of retina | 13 | $505 | $34 |
| Ultrasound scan of cornea to determine thickness | 16 | $231 | $9 |
2019: 4 services
| Transplantation of outer layer of corneal tissue | 19 | $3,960 | $180 |
| Short return visit (20+ min) | 38 | $1,713 | $40 |
| Return visit (30+ min) | 14 | $919 | $66 |
| Imaging of retina | 11 | $267 | $22 |
2018: 2 services
| Transplantation of outer layer of corneal tissue | 13 | $2,346 | $180 |
| Short return visit (20+ min) | 24 | $1,218 | $45 |
Drugs they prescribed that Part D paid
$530,683
Pharmacies billed $530,683 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
454 generic and 854 brand-name prescriptions · $530,683 in drug cost · 21 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 120 | $144,931 | $1,208 |
| Cequa | 85 | $55,981 | $659 |
| Xiidra | 43 | $43,680 | $1,016 |
| Rocklatan | 73 | $26,178 | $359 |
| Tyrvaya | 32 | $22,015 | $688 |
See all 25 drugs
| Restasis | 120 | $144,931 | $1,208 |
| Cequa | 85 | $55,981 | $659 |
| Xiidra | 43 | $43,680 | $1,016 |
| Rocklatan | 73 | $26,178 | $359 |
| Tyrvaya | 32 | $22,015 | $688 |
| Miebo | 25 | $18,953 | $758 |
| Vyzulta | 34 | $16,389 | $482 |
| Combigan | 18 | $10,107 | $561 |
| Travoprost | 25 | $9,477 | $379 |
| Prednisolone Acetate | 117 | $7,384 | $63 |
| Prolensa | 20 | $7,105 | $355 |
| Latanoprost | 239 | $6,002 | $25 |
| Cyclosporine | 13 | $5,387 | $414 |
| Alphagan P | 11 | $4,834 | $439 |
| Brimonidine | 34 | $4,513 | $133 |
| Timolol Maleate | 67 | $4,048 | $60 |
| Moxifloxacin | 102 | $2,308 | $23 |
| Loteprednol Etabonate | 15 | $2,245 | $150 |
| Valacyclovir | 30 | $2,007 | $67 |
| Ketorolac Tromethamine | 28 | $560 | $20 |
| Atropine Sulfate | 12 | $518 | $43 |
| Doxycycline Hyclate | 18 | $467 | $26 |
| Ofloxacin | 12 | $182 | $15 |
| Dorzolamide-Timolol | 20 | $180 | $9 |
| Tobramycin | 15 | $152 | $10 |
Year by year
| 2024 | 1,308 | 268 | None | 65% | $530,683 |
| 2023 | 980 | 226 | None | 67% | $676,382 |
| 2022 | 414 | 100 | None | 50% | $91,036 |
| 2021 | 465 | 111 | None | 46% | $78,780 |
| 2020 | 193 | 58 | None | 56% | $46,414 |
| 2019 | 401 | 143 | 0% (0) | 62% | $63,804 |
| 2018 | 285 | 125 | 0% (0) | 54% | $39,236 |
| 2017 | 117 | 53 | None | 47% | $10,543 |
| 2016 | 103 | 14 | 0% (0) | 41% | $4,453 |
| 2015 | 75 | 32 | 0% (0) | 47% | $3,782 |
| 2014 | 15 | None | None | None | $548 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Restasis | 80 | $94,794 | $1,185 |
| Cequa | 72 | $43,804 | $608 |
| Xiidra | 30 | $23,403 | $780 |
| Rocklatan | 47 | $19,894 | $423 |
| Prolensa | 43 | $14,311 | $333 |
| Tyrvaya | 18 | $12,314 | $684 |
| Vyzulta | 19 | $10,583 | $557 |
| Rhopressa | 15 | $8,399 | $560 |
| Alphagan P | 20 | $7,814 | $391 |
| Latanoprost | 180 | $7,325 | $41 |
| Combigan | 13 | $6,705 | $516 |
| Prednisolone Acetate | 98 | $6,438 | $66 |
| Travoprost | 16 | $5,773 | $361 |
| Brimonidine | 17 | $3,564 | $210 |
| Moxifloxacin | 75 | $3,171 | $42 |
| Valacyclovir | 23 | $2,814 | $122 |
| Timolol Maleate | 41 | $2,813 | $69 |
| Loteprednol Etabonate | 11 | $2,110 | $192 |
| Doxycycline Hyclate | 24 | $754 | $31 |
| Dorzolamide-Timolol | 22 | $480 | $22 |
| Ofloxacin | 19 | $343 | $18 |
| Tobramycin | 11 | $107 | $10 |
2022: 13 drugs
| Restasis | 19 | $28,696 | $1,510 |
| Xiidra | 17 | $15,778 | $928 |
| Cequa | 14 | $7,773 | $555 |
| Prolensa | 14 | $4,574 | $327 |
| Brimonidine | 30 | $4,154 | $138 |
| Prednisolone Acetate | 53 | $3,790 | $72 |
| Loteprednol Etabonate | 12 | $2,037 | $170 |
| Doxycycline Hyclate | 26 | $1,544 | $59 |
| Valacyclovir | 13 | $1,056 | $81 |
| Latanoprost | 62 | $725 | $12 |
| Moxifloxacin | 14 | $553 | $39 |
| Ofloxacin | 33 | $438 | $13 |
| Timolol Maleate | 20 | $181 | $9 |
2021: 12 drugs
| Xiidra | 34 | $26,686 | $785 |
| Restasis | 17 | $21,077 | $1,240 |
| Prednisolone Acetate | 64 | $4,417 | $69 |
| Brimonidine | 17 | $2,148 | $126 |
| Doxycycline Hyclate | 31 | $1,498 | $48 |
| Moxifloxacin | 24 | $1,401 | $58 |
| Valacyclovir | 15 | $693 | $46 |
| Dexamethasone Sodium Phosphate | 27 | $673 | $25 |
| Latanoprost | 53 | $560 | $11 |
| Ofloxacin | 40 | $547 | $14 |
| Ketorolac Tromethamine | 23 | $294 | $13 |
| Timolol Maleate | 13 | $158 | $12 |
2020: 5 drugs
| Restasis | 14 | $14,551 | $1,039 |
| Xiidra | 17 | $13,359 | $786 |
| Prednisolone Acetate | 37 | $2,204 | $60 |
| Moxifloxacin | 19 | $1,214 | $64 |
| Ofloxacin | 13 | $168 | $13 |
2019: 10 drugs
| Restasis | 25 | $19,652 | $786 |
| Prednisolone Acetate | 94 | $6,499 | $69 |
| Valacyclovir | 32 | $6,332 | $198 |
| Durezol | 23 | $4,803 | $209 |
| Lotemax | 15 | $4,244 | $283 |
| Brimonidine | 18 | $2,231 | $124 |
| Fluorometholone | 28 | $2,130 | $76 |
| Moxifloxacin | 19 | $1,071 | $56 |
| Latanoprost | 26 | $383 | $15 |
| Timolol Maleate | 23 | $324 | $14 |
2018: 8 drugs
| Lotemax | 15 | $3,536 | $236 |
| Prednisolone Acetate | 45 | $3,443 | $77 |
| Alphagan P | 11 | $3,354 | $305 |
| Brimonidine | 23 | $2,761 | $120 |
| Valacyclovir | 15 | $2,065 | $138 |
| Moxifloxacin | 15 | $752 | $50 |
| Latanoprost | 27 | $543 | $20 |
| Timolol Maleate | 29 | $285 | $10 |
2017: 5 drugs
| Alphagan P | 14 | $3,841 | $274 |
| Brimonidine | 12 | $1,227 | $102 |
| Prednisolone Acetate | 14 | $918 | $66 |
| Latanoprost | 15 | $456 | $30 |
| Timolol Maleate | 17 | $163 | $10 |
2016: 3 drugs
| Latanoprost | 37 | $432 | $12 |
| Dorzolamide | 21 | $430 | $20 |
| Timolol Maleate | 19 | $125 | $7 |
Money from drug and device companies
$1,327 in 2025
| 2025 | 8 | 16 | None | $1,327 |
| 2024 | 9 | 31 | None | $1,678 |
| 2023 | 11 | 39 | None | $1,580 |
| 2022 | 9 | 15 | None | $658 |
| 2021 | 9 | 14 | None | $265 |
| 2020 | 2 | 2 | None | $46 |
| 2019 | 4 | 7 | None | $375 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Unity | $868 | 2 payments
|
| Sight Sciences | Omni Surgical System | $162 | 4 payments
|
| Dompe US | Oxervate | $111 | 4 payments
|
| Glaukos | Photrexa Viscous and Photrexa | $60 | 2 payments
|
| Abbvie | Lumigan | $35 | 1 payment
|
| Amgen | Tepezza | $33 | 1 payment
|
See all 16 published payments
| Alcon Vision | Long term medical supply or device loan · 2025-12-31 | Unity | $838 |
| Glaukos | Meals · 2025-11-20 | Photrexa Viscous and Photrexa | $33 |
| Abbvie | Meals · 2025-11-17 | Lumigan | $35 |
| Alcon Vision | Meals · 2025-11-13 | Tryptyr | $30 |
| Sight Sciences | Meals · 2025-10-19 | Omni Surgical System | $30 |
| Sight Sciences | Meals · 2025-10-18 | Omni Surgical System | $32 |
| Dompe US | Meals · 2025-09-25 | Oxervate | $28 |
| Amgen | Meals · 2025-08-14 | Tepezza | $33 |
| Glaukos | Meals · 2025-08-13 | Photrexa Viscous and Photrexa | $27 |
| Dompe US | Meals · 2025-07-17 | Oxervate | $26 |
| Sight Sciences | Meals · 2025-05-22 | Omni Surgical System | $94 |
| Tarsus Pharmaceuticals | Meals · 2025-05-13 | Xdemvy | $27 |
| Sun Pharmaceutical Industries | Meals · 2025-04-29 | Cequa | $32 |
| Dompe US | Meals · 2025-04-08 | Oxervate | $25 |
| Dompe US | Meals · 2025-03-13 | Oxervate | $32 |
| Sight Sciences | Meals · 2025-01-13 | Omni Surgical System | $5 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,678
| Glaukos | Idose | $365 | 5 payments
|
| Amgen | Tepezza | $350 | 6 payments
|
| Alcon Vision | Rocklatan | $323 | 4 payments
|
| Sight Sciences | Omni Surgical System | $283 | 2 payments
|
| Dompe US | Oxervate | $118 | 5 payments
|
| Sun Pharmaceutical Industries | Cequa | $109 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $83 | 3 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $30 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $16 | 1 payment
|
2023: $1,580
| Alcon Vision | Clareon | $461 | 6 payments
|
| RxSight | Rxsight Contact Lens | $309 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $183 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $144 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $131 | 5 payments
|
| Kowa Pharmaceuticals America | Seglentis | $129 | 8 payments
|
| Sun Pharmaceutical Industries | Cequa | $118 | 4 payments
|
| Glaukos | Kxl System (Not Refurbished) | $50 | 2 payments
|
| Dompe US | Oxervate | $22 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $16 | 1 payment
|
| Abbvie | Durysta | $15 | 1 payment
|
2022: $658
| Dompe US | Oxervate | $266 | 3 payments
|
| Genentech USA | Vabysmo | $142 | 1 payment
|
| Kowa Pharmaceuticals America | Seglentis | $89 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $61 | 2 payments
|
| Abbvie | Durysta | $26 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $21 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $18 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $18 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $18 | 1 payment
|
2021: $265
| Kala Pharmaceuticals | Inveltys | $61 | 4 payments
|
| Allergan | Durysta | $43 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $33 | 2 payments
|
| Dompe US | Oxervate | $28 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Infuse | $23 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $22 | 1 payment
|
| Johnson & Johnson Surgical Vision | Lipiflow System Activator II (Disposable | $19 | 1 payment
|
| Glaukos | Kxl System | $19 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $17 | 1 payment
|
2020: $46
| Dompe US | Oxervate | $31 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $14 | 1 payment
|
2019: $375
| Alcon Vision | Centurion | $217 | 3 payments
|
| Dompe US | Oxervate | $123 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $21 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669891610
- Licence
- CA A139451, HI 20306California A139451: Cancelled
- Trained
- University of California, Irvine, California College of Medicine, 2014
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0120X (207WX0120X); Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 650 Iwilei Rd Ste 210, Honolulu, HI, 96817
- NPI first listed
- 2014-04-07
- NPI last updated
- 2019-07-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1356 Lusitana St, Honolulu, HI, 96813 · 33 Lono Ave Ste 260, Kahului, HI, 96732 · 300 Pasteur Dr, Stanford, CA, 94305